GeneDx Holdings Analyst Price Targets

Wall Street analyst price targets and consensus rating for GeneDx Holdings (WGS).

Price Target Range — 11 Quarters

Analyst Consensus — 10 Analysts

9Buy

1Hold

Consensus RatingBuy# Analysts10Avg. Consensus PT$88Upside to Avg. PT+35.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 1, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$74→$83
Aug 4, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$75→$90
Aug 4, 2026	BTIG	Mark Massaro	Maintained	Buy	$90
Jun 29, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$70→$74
Jun 23, 2026	Piper Sandler	David Westenberg	PT Raise	Overweight	$50→$63
May 5, 2026	Canaccord Genuity	Kyle Mikson	PT Cut	Buy	$100→$75
May 5, 2026	Wells Fargo	Brandon Couillard	PT Cut	Overweight	$155→$75
May 5, 2026	Guggenheim	Subbu Nambi	PT Cut	Buy	$100→$70
May 5, 2026	BTIG	Mark Massaro	PT Cut	Buy	$170→$90
Apr 20, 2026	Canaccord Genuity	Kyle Mikson	PT Cut	Buy	$170→$100
Mar 30, 2026	Guggenheim	Subbu Nambi	PT Cut	Buy	$170→$100
Feb 24, 2026	Piper Sandler	David Westenberg	PT Cut	Overweight	$160→$130
Feb 24, 2026	BTIG	Mark Massaro	PT Cut	Buy	$200→$170
Feb 9, 2026	Wells Fargo	Brandon Couillard	Upgrade	Equal-Weight→Overweight	$155
Dec 22, 2025	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$160→$170
Dec 15, 2025	Wells Fargo	Brandon Couillard	PT Raise	Equal-Weight	$140→$155
Dec 12, 2025	BTIG	Mark Massaro	PT Raise	Buy	$165→$200
Nov 4, 2025	Wells Fargo	Brandon Couillard	PT Raise	Equal-Weight	$95→$140
Oct 29, 2025	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$155→$160
Oct 29, 2025	Guggenheim	Subbu Nambi	PT Raise	Buy	$115→$170

Analyst Ratings News

PRO
Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $83

Guggenheim analyst Subbu Nambi maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and raises the price target from $74 to $83.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on GeneDx Holdings, Raises Price Target to $90

Canaccord Genuity analyst Kyle Mikson maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and raises the price target from $75 to $90.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on GeneDx Holdings, Maintains $90 Price Target

BTIG analyst Mark Massaro reiterates GeneDx Holdings (NASDAQ:WGS) with a Buy and maintains $90 price target.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $74

Guggenheim analyst Subbu Nambi maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and raises the price target from $70 to $74.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on GeneDx Holdings, Raises Price Target to $63

Piper Sandler analyst David Westenberg maintains GeneDx Holdings (NASDAQ:WGS) with a Overweight and raises the price target from $50 to $63.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on GeneDx Holdings, Lowers Price Target to $75

Canaccord Genuity analyst Kyle Mikson maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and lowers the price target from $100 to $75.

Benzinga Newsdesk

GeneDx Holdings Corp

GeneDx Holdings Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $83

PRO
Canaccord Genuity Maintains Buy on GeneDx Holdings, Raises Price Target to $90

PRO
BTIG Reiterates Buy on GeneDx Holdings, Maintains $90 Price Target

PRO
Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $74

PRO
Piper Sandler Maintains Overweight on GeneDx Holdings, Raises Price Target to $63

PRO
Canaccord Genuity Maintains Buy on GeneDx Holdings, Lowers Price Target to $75

People Also Watch

People Also Watch

GeneDx Holdings Corp

GeneDx Holdings Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $83

PROCanaccord Genuity Maintains Buy on GeneDx Holdings, Raises Price Target to $90

PROBTIG Reiterates Buy on GeneDx Holdings, Maintains $90 Price Target

PROGuggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $74

PROPiper Sandler Maintains Overweight on GeneDx Holdings, Raises Price Target to $63

PROCanaccord Genuity Maintains Buy on GeneDx Holdings, Lowers Price Target to $75

People Also Watch

People Also Watch

PRO
Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $83

PRO
Canaccord Genuity Maintains Buy on GeneDx Holdings, Raises Price Target to $90

PRO
BTIG Reiterates Buy on GeneDx Holdings, Maintains $90 Price Target

PRO
Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $74

PRO
Piper Sandler Maintains Overweight on GeneDx Holdings, Raises Price Target to $63

PRO
Canaccord Genuity Maintains Buy on GeneDx Holdings, Lowers Price Target to $75